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Severe neonatal epilepsies with suppression-burst pattern are epileptic syndromes with either neonatal onset or
onset during the first months of life. These disorders are characterized by a typical electroencephalogram pattern—
namely, suppression burst, in which higher-voltage bursts of slow waves mixed with multifocal spikes alternate
with isoelectric suppression phases. Here, we report the genetic mapping of an autosomal recessive form of this
condition to chromosome 11p15.5 and the identification of a missense mutation (p.Pro206Leu) in the gene encoding
one of the two mitochondrial glutamate/H+ symporters (SLC25A22, also known as “GC1”). The mutation co-
segregated with the disease and altered a highly conserved amino acid. Functional analyses showed that glutamate
oxidation in cultured skin fibroblasts from patients was strongly defective. Further studies in reconstituted proteo-
liposomes showed defective [14C]glutamate uniport and [14C]glutamate/glutamate exchange by mutant protein. More-
over, expression studies showed that, during human development, SLC25A22 is specifically expressed in the brain,
within territories proposed to contribute to the genesis and control of myoclonic seizures. These findings provide
the first direct molecular link between glutamate mitochondrial metabolism and myoclonic epilepsy and suggest
potential insights into the pathophysiological bases of severe neonatal epilepsies with suppression-burst pattern.
Severe neonatal epilepsies with suppression-burst pat-
tern are early-onset epileptic syndromes characterized by
a typical electroencephalogram (EEG) pattern—namely,
suppression burst, in which higher-voltage bursts of slow
waves mixed with multifocal spikes alternate with iso-
electric suppression phases (Ohtsuka et al. 1993; Vige-
vano and Bartuli 2002). Early myoclonic encephalopa-
thy (EME), first described by Aicardi and Goutie`res in
1978, is characterized by a very early onset (during the
1st month of life); erratic, fragmentary myoclonus; mas-
sive myoclonus; partial motor seizures; and late tonic
spasms (Aicardi and Goutie`res 1978; Aicardi 1992). The
prognosis of EME is poor, with no effective treatment,
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and children with the condition either die within 1–2
years after birth or survive in a persistent vegetative state.
The lack of consistent neuropathological features sug-
gests that etiology may vary from case to case. EME has
been reported in nonketotic hyperglycinemia (MIM
605899), propionic acidemia (MIM 606054), and some
malformative disorders (Guerrini et al. 2003). In most
cases, however, the underlying mechanism of these dis-
orders remains unknown.
Early infantile epileptic encephalopathy, which includes
West syndrome and Lennox-Gastaut syndrome, is char-
acterized by a very early onset (during the first few months
of life), frequent tonic spasms, and a suppression-burst
EEG pattern. Partial motor seizures may also occur. The
course is severe, with early death or marked psychomotor
retardation and intractable seizures with frequent evo-
lution to West syndrome. Brain imaging usually discloses
gross structural abnormalities, in the majority of cases.
Metabolic disorders are also present in a few cases, but
the proportion of cryptogenic cases is high.
We have investigated a sibship of four affected chil-
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Figure 1 A, Pedigree and haplotype of the family. The blackened symbols indicate affected individuals, and the haplotype segregation
with EME is shown. A plus sign () p wild-type sequence; m p mutation. B, Physical map of the critical interval, indicating the candidate
genes in this region of chromosome 11p15.
dren (two girls and two boys) and four healthy children
born to Arab Muslim parents from Jerusalem who are
first cousins (fig. 1A). The proband (patient II.7 in fig.
1A) was first examined at age 2 d because of intractable
seizures and neonatal hypotonia. At age 3 years, com-
puterized tomography of the head revealed brain atro-
phy, and EEG showed myoclonic seizures and burst sup-
pression. Nonketotic hyperglycinemia was ruled out. His
eldest sister (patient II.1 in fig. 1A) also had hypotonia
and seizures a few hours after birth. Computerized to-
mography of the head at age 3 years showed brain at-
rophy. Electroretinogram (ERG) was normal, whereas
visual-evoked potential (VEP) showed a low amplitude
signal and a slow response suggestive of abnormal vis-
ual nerve-conduction velocity. Electron-microscopy ex-
amination of a skin biopsy ruled out storage disease,
and high-resolution karyotype was normal. The eldest
brother (patient II.2 in fig. 1A) also had hypotonia and
neonatal myoclonic seizures. Plasma amino acid, copper,
biotinidase lactate, carnitine, and urinary organic acids
were normal. He died at age 8 years. Finally, the fourth
affected child (patient II.4 in fig. 1A) was hypotonic and
presented with neonatal seizures. At age 7 wk, ERG-
VEP examination showed abnormal conduction and
retinal function. At 3 years of age, brain magnetic res-
onance imaging (MRI) showed subarachnoid enlarge-
ment, especially in the frontal region. EEG showed
myoclonic seizures with burst suppression. Extensive
metabolic work-up was consistently normal. Electron-
microscopy examination of skin fibroblasts and optic
examination of muscle biopsy were normal as well. In
conclusion, very-early-onset intractable myoclonus epi-
lepsy with progressive microcephaly, periodic EEG with
suppression burst, and abnormal VEPs evolving into a
severe encephalopathy and spasticity were consistent
features in the four affected siblings.
A genomewide screening, performed using the Perkin
Elmer Biosystems linkage mapping set (version 1), iden-
tified a single homozygous marker, D11S4046, on chro-
mosome 11p15.5 in the four affected sibs. Further
marker typing and haplotype analyses reduced the ge-
netic interval to a 2.5-Mb interval between marker
D11S4088 and the telomere (fig. 1A). Linkage analysis
using LINKAGE software (version M-LINK) gave a Zmax
of 3.06 at at the D11S4177 locus. Concordantvp 0
data from the National Center for Biotechnology Infor-
mation (NCBI) and the University of California–Santa
Cruz (UCSC) database genome browsers indicate that
54 known genes and ∼25 EST clusters map to this in-
terval. On the basis of the hypothesis that this condition
is of metabolic origin, nine genes were considered as
candidates (fig. 1B). Among them, SLC25A22 (also
known as “GC1”) was regarded as a strong candidate
gene because of position, expression, and function. The
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Figure 2 Respiration and mitochondrial substrate oxidation in cultured skin fibroblasts from patients and controls. A, After polarographic
measurement of intact cell respiration, digitonin-permeabilized cells were loaded with adenosine diphosphate (ADP) and amino oxyacetate. This
compound inhibits the aspartate-amino transferase enzyme activity (see panel C). A subsequent addition of glutamate allowed estimation of
mitochondrial glutamate oxidation under phosphorylation conditions (i.e., presence of ADP). Note the lack of glutamate-triggered oxygen
uptake in patient cells. A similar succinate oxidation rate was measured in control and patient cells. Numbers along the traces are nmol O2
consumed per minute per microgram of protein. B, Various ratios showing the profound defect of glutamate oxidation (GOx) in patient cells
(unblackened boxes), as compared with cell respiration (R) or succinate oxidation (SOx). Values are the means (1 SD) of six experiments.
C, Features of mitochondrial glutamate metabolism, with inner membrane–associated glutamate-H symporter (1) and aspartate/glutamate
antiporter (4), and the matrix-located enzymes, glutamate dehydrogenase (2) and amino-oxyacetate–sensitive aspartate-amino transferase (3).
AOA p amino oxyacetate; Asp p aspartate; Glut p glutamate; a-KG p a-ketoglutarate; and OAAp oxaloacetate. Experimental conditions
were as described in the “Methods” section of appendix A (online only).
SLC25 gene family encodes mitochondrial carriers that
transport a variety of metabolites across the inner mi-
tochondrial membrane (Palmieri 2004). The SLC25A22
protein catalyzes either the cotransport of L-glutamate
with H or its exchange with OH (Fiermonte et al.
2002). The genomic structure of the human SLC25A22
gene was identified by alignment of the cDNA sequence
(GenBank accession number NM_024698) with the se-
quence of PAC clone RP13-569C6 (GenBank accession
number AC132936). Nine coding exons were identified,
and primers were designed for direct sequencing of all
exons and exon-intron junctions (see table A1 [online
only]). Homozygosity for a missense mutation in exon
8 of the SLC25A22 gene was detected in patient II.1,
with the change of a proline into a leucine in the protein
(p.Pro206Leu). Sequence analyses showed cosegregation
of the mutation with the disease in all affected individ-
uals, whereas both parents were heterozygous (fig. 1A).
This mutation was not found in 200 unrelated control
individuals (100 of Arab origin and 100 of various ethnic
origins). Real-time PCR analysis of fibroblast RNAs
from patient II.1 detected normal amounts of the mutant
gene transcripts, compared with those of various con-
trols (data not shown). To estimate the prevalence of
SLC25A22 mutations in EME, we collected DNA from
25 unrelated children with EME and progressive mi-
crocephaly and sequenced the coding region of the
SLC25A22 gene, but no mutation was identified.
The changed proline residue is highly conserved across
species in the glutamate and aspartate/glutamate carriers
(fig. A1 [online only]), suggesting that this base change
might impair glutamate transport. To test this hypoth-
esis, we investigated the oxidation of glutamate in cul-
tured skin fibroblasts from patients (fig. 2A and the
“Methods” section of appendix A [online only]). Be-
cause a balanced proportion of oxidizing activities is
consistently observed in cultured fibroblasts and is re-
quired for optimum function of the respiratory chain
and for continuous metabolic fluxes, activity ratios
rather than absolute values were used to evaluate glu-
tamate oxidation efficiency. Figure 2B presents the mean
( 1 SD) of six independent experiments. Under stan-
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Figure 3 Kinetics of [14C]glutamate uniport and [14C]glutamate/
glutamate exchange catalyzed by the wild-type and mutated GC1 pro-
teins. Proteoliposomes were reconstituted with the recombinant wild-
type (blackened symbols) or the mutated GC1 protein (unblackened
symbols). At time zero, 1 mM [14C]glutamate was added to the pro-
teoliposomes containing 10 mM glutamate (exchange [circles]) or 10
mM NaCl and no substrates (uniport [triangles]). At the indicated time
intervals, the uptake of labeled substrate was stopped by addition of
30 mM pyridoxal 5′-phosphate and 10 mM bathophenantroline. Data
are means ( SD) of four independent experiments. No transport
activity was detected when the mutant protein was used.
dard conditions, polarographic studies showed normal
cell respiration by intact cells, indicating that glutamate
does not represent a major respiratory substrate, at least
in the cell type tested. However, after permeabilization
of cell membranes by digitonin in the presence of amino-
oxyacetate, a specific inhibitor of amino-aspartate trans-
ferase (fig. 2C), patient cells failed to normally oxidize
glutamate, as compared with controls, whereas oxida-
tion of another substrate, succinate, was normal in pa-
tient cells (fig. 2B). Simultaneous spectrophotometric
studies detected similar glutamate dehydrogenase activ-
ities in patient and control cells (data not shown). These
results provide evidence that patient cells show a clear
defect in mitochondrial glutamate metabolism.
To get further insight into the functional consequences
of this base change, wild-type and mutant SLC25A22
proteins were overexpressed in Escherichia coli and were
purified (see the “Methods” section of appendix A [on-
line only]). Equivalent amounts of neosynthesized pro-
teins were then used for in vitro reconstitution of the
transporter into liposomes (Palmieri et al. 1995). Obser-
vation of the time course of [14C]glutamate uniport and
[14C]glutamate/glutamate exchange in reconstituted pro-
teoliposomes showed that the wild-type protein efficiently
catalyzed glutamate transport and exchange, whereas, de-
spite normal insertion of the mutant protein in the lipo-
somal membrane, neither transport nor exchange activ-
ities were detected with the mutant construct (fig. 3).
Northern blot analysis of human fetal tissues revealed
a strong hybridization signal with brain mRNA, where-
as a very faint signal was detected in the lung, kidney,
and liver mRNAs (data not shown). Further expression
analyses, by use of in situ hybridization experiments,
detected no signal in 32-, 44-, and 47-d-old human em-
bryos (data not shown). By contrast, at 15 wk of devel-
opment, prominent expression was detected in the cortex
(fig. 4A–4D), the hippocampal formation (fig. 4E and
4F), and the pontine nuclei (data not shown). In the
cortex, signal was detected in all the laminae of the cor-
tical plate, from laminae II through VI. In the hippo-
campal formation, SLC25A22 was uniformely ex-
pressed in the CA1, CA2, and CA3 pyramidal cell fields
as well as in the granular layer of the dentate gyrus. No
expression was detected in the spinal cord. At a later
stage (20 wk of development), the highest gene expres-
sion was detected in the cerebral cortex, the brain stem,
and the cerebellum (fig. 4G–4L). In the brainstem, a
moderate-to-high level of SLC25A22 mRNA expression
was observed in the red nuclei, the substantia nigra, and
the cranial nerves nuclei III, as well as in the olivary
complexes. Finally, SLC25A22 expression was also de-
tected in the cerebellum, within the dentate nucleus.
Mutations in mitochondrial carriers in humans have
been reported elsewhere (Palmieri 2004), but none of
these mutations have been shown to cause early myo-
clonic epilepsy. SLC25A13 (encoding aspartate/gluta-
mate carrier 2) mutations cause type II citrullinemia
(MIM 603471), SLC25A15 (encoding ornithine carrier
1) mutations are associated with hyperornithinaemia-
hyperammonaemia-homocitrulliniria syndrome (triple
H syndrome [MIM 238970]), SLC20A19 (encoding
deoxynucleotide carrier) mutations cause Amish micro-
cephaly (MIM 607196), SLC25A4 mutations cause au-
tosomal dominant progressive external ophthalmoplegia
(adPEO [MIM 157640]), and SLC25A20 (encoding car-
nithine/acylcarnithine carrier) mutations are responsible
for Stanley syndrome (MIM 212138). These genes en-
code proteins involved in the urea cycle, mtDNA me-
tabolism, or translocation of fatty acids into the mito-
chondria. An increasing number of studies have also
shown that mitochondrial dysfunction can result in sei-
zures and drug-resistant forms of severe epilepsy (Wal-
lace et al. 1988; Goto et al. 1990; Degoul et al. 1995).
Presumably, all these mutations act by impairing mito-
chondrial respiratory chain function and ATP synthe-
sis. By contrast, the present study provides the first ev-
idence that, despite normal oxidative phosphorylation,
impaired mitochondrial glutamate import/metabolism
leads to an alteration of neuronal excitability, possibly
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Figure 4 SLC25A22 gene expression in the 15-wk-old (A–F)
and 20-wk-old (G–L) fetal human brain. Sections counterstained with
hematoxylin and eosin are show under bright-field (A, C, E, G, I, and
K) and dark-field illumination to reveal the localization of the in situ
hybridization signal (B, D, F, H, J, and L). CP p cortical plate; SN
p substantia nigra; NR p nucleus ruber; SON p superior olive nu-
cleus; SF p sylvian fissure; OC p olivary complex; and PF p pon-
tocerebellar fibers.
linking glutamate transport to the pathogenesis of my-
oclonic seizures.
Previously published data regarding SLC25A22 ex-
pression showed that it is ubiquitously expressed in
adult tissues and is particularly abundant in liver and
pancreas (Fiermonte et al. 2002). To understand why
the SLC25A22 mutation results in a pure neurological
phenotype, we studied the SLC25A22 gene expression
during human development. Northern blot analyses
and in situ hybridization experiments confirmed that
SLC25A22 expression is restricted to the brain. Inter-
estingly, SLC25A22 expression was found within ter-
ritories proposed to contribute to the genesis and control
of myoclonic seizures. It is worth remembering that the
substantia nigra is the central part of the nigral control
of the epilepsy system that, when activated, inhibits sei-
zure generation and propagation (Depaulis et al. 1994;
Deransart et al. 2001). More interesting is that several
cases of neonatal epilepsy with suppression-burst EEG
pattern and olivary-dentate dysplasia have been reported
(Harding and Boyd 1991; Robain and Dulac 1992), and
the olivocerebellar pathway was proposed to contribute
to the genesis of myoclonic seizures. Several lines of ev-
idence, based on immunohistochemical, pharmacologi-
cal, and electrophysiological experiments, suggest that
glutamate plays an important role in olivocerebellar
transmission (Clements et al. 1987; Zhang et al. 1990;
Trinka et al. 2001). The mitochondrial component of
the glutamate system may thus be a key player in this
pathway.
How mutations in SLC25A22 cause epilepsy remains
an open question. Neuronal dysfunction may result from
an abnormal glutamate pool in the cytoplasm, from a
secondary alteration of electron flow through the respi-
ratory chain, or from impaired oxygen handling in a
discrete subset of neurons. The mitochondrion is a major
site of ammonia synthesis, especially through the glu-
tamate dehydrogenase reaction. Hence, impaired am-
monia synthesis (due to altered glutamate import) could
also play a role in the pathogenesis of the disease.
Epilepsy might also result from abnormal glutamate
turnover. Indeed, it is worth remembering that glutamate
is the major excitatory neurotransmitter in the mam-
malian brain. Efficient neurotransmission requires (1)
low intrasynaptic glutamate concentration, so as to max-
imize the signal-to-noise ratio, and (2) rapid replacement
of the transmitter that is released from presynaptic ends.
This is achieved by the rapid uptake of glutamate into
astrocytes, which converts glutamate into glutamine,
thus ensuring the replenishment of the internal neuronal
glutamate pool. In addition, high extracellular glutamate
concentrations have been identified as a likely cause of
epileptic seizures in mesial temporal lobe epilepsy (Dur-
ing and Spencer 1993). Thus, glial cells may play an
important role in the pathogenesis of the disorder. This
hypothesis is also favored by the observation that, at
variance with neurons, adult glial cells do not signif-
icantly express the aspartate/glutamate carriers (Ramos
et al. 2003), so that glial mitochondrial glutamate import
may be dependent on glutamate carrier activity only. We
therefore speculate that impaired GC1 function could
result in a severe alteration of glutamate metabolism in
glial cells.
Intact glutamate metabolism is crucial for amino acid
synthesis and oxidation, for ureogenesis, and for normal
function of the CNS. The identification of mutant GC1
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as an etiology of early myoclonic epilepsy emphasizes the
unexpected importance of the mitochondrial component
of glutamate metabolism in normal brain function, thus
opening a novel field in the pathophysiology of EME.
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